Search

Your search keyword '"Yan, Lun-Jie"' showing total 23 results
Start Over Author "Yan, Lun-Jie" Search Limiters Available in Library Collection
23 results on '"Yan, Lun-Jie"'

2. Efficacy and safety of immune checkpoint inhibitors for hepatocellular carcinoma patients with macrovascular invasion or extrahepatic spread: a systematic review and meta-analysis of 54 studies with 6187 hepatocellular carcinoma patients

Author

Han, Cheng-Long, Tian, Bao-Wen, Yan, Lun-Jie, Ding, Zi-Niu, Liu, Hui, Mao, Xin-Cheng, Tian, Jin-Cheng, Xue, Jun-Shuai, Tan, Si-Yu, Dong, Zhao-Ru, Yan, Yu-Chuan, Hong, Jian-Guo, Chen, Zhi-Qiang, Wang, Dong-Xu, and Li, Tao

Published
2023
Full Text
View/download PDF

8. Identification of the most effective subgroup of advanced hepatocellular carcinoma from immune checkpoint blocker treatment: a meta-analysis

Author

Liu, Hui, primary, Yang, Chun-Cheng, additional, Ma, Yun-Long, additional, Yang, Ya-Fei, additional, Yan, Lun-Jie, additional, Ding, Zi-Niu, additional, Xue, Jun-Shuai, additional, Yang, Long-Shan, additional, Yan, Yu-Chuan, additional, Dong, Zhao-Ru, additional, Wang, Dong-Xu, additional, Chen, Zhi-Qiang, additional, Hong, Jian-Guo, additional, and Li, Tao, additional

Published
2023
Full Text
View/download PDF

9. A novel prognostic scoring model based on copper homeostasis and cuproptosis which indicates changes in tumor microenvironment and affects treatment response

Author

Ma, Yun-Long, primary, Yang, Ya-Fei, additional, Wang, Han-Chao, additional, Yang, Chun-Cheng, additional, Yan, Lun-Jie, additional, Ding, Zi-Niu, additional, Tian, Bao-Wen, additional, Liu, Hui, additional, Xue, Jun-Shuai, additional, Han, Cheng-Long, additional, Tan, Si-Yu, additional, Hong, Jian-Guo, additional, Yan, Yu-Chuan, additional, Mao, Xin-Cheng, additional, Wang, Dong-Xu, additional, and Li, Tao, additional

Published
2023
Full Text
View/download PDF

12. Systemic immune–inflammation index predicts prognosis of cancer immunotherapy: systemic review and meta-analysis

Author

Tian, Bao-Wen, primary, Yang, Ya-Fei, additional, Yang, Chun-Cheng, additional, Yan, Lun-Jie, additional, Ding, Zi-Niu, additional, Liu, Hui, additional, Xue, Jun-Shuai, additional, Dong, Zhao-Ru, additional, Chen, Zhi-Qiang, additional, Hong, Jian-Guo, additional, Wang, Dong-Xu, additional, Han, Cheng-Long, additional, Mao, Xin-Cheng, additional, and Li, Tao, additional

Published
2022
Full Text
View/download PDF

14. The Prognostic Value of Natural Killer Cells and Their Receptors/Ligands in Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis

Author

Xue, Jun-Shuai, primary, Ding, Zi-Niu, additional, Meng, Guang-Xiao, additional, Yan, Lun-Jie, additional, Liu, Hui, additional, Li, Hai-Chao, additional, Yao, Sheng-Yu, additional, Tian, Bao-Wen, additional, Dong, Zhao-Ru, additional, Chen, Zhi-Qiang, additional, Hong, Jian-Guo, additional, Wang, Dong-Xu, additional, and Li, Tao, additional

Published
2022
Full Text
View/download PDF

16. The Predictive Potential of the Baseline C-Reactive Protein Levels for the Efficiency of Immune Checkpoint Inhibitors in Cancer Patients: A Systematic Review and Meta-Analysis

Author

Han, Cheng-Long, primary, Meng, Guang-Xiao, additional, Ding, Zi-Niu, additional, Dong, Zhao-Ru, additional, Chen, Zhi-Qiang, additional, Hong, Jian-Guo, additional, Yan, Lun-Jie, additional, Liu, Hui, additional, Tian, Bao-Wen, additional, Yang, Long-Shan, additional, Xue, Jun-Shuai, additional, and Li, Tao, additional

Published
2022
Full Text
View/download PDF

18. Somatic mutation and expression of BAP1 in hepatocellular carcinoma: an indicator for ferroptosis and immune checkpoint inhibitor therapies

Author

Yan, Yu-Chuan, primary, Meng, Guang-Xiao, additional, Ding, Zi-Niu, additional, Liu, Yan-Feng, additional, Chen, Zhi-Qiang, additional, Yan, Lun-Jie, additional, yang, Ya-Fei, additional, Liu, Hui, additional, Yang, Chun-Cheng, additional, Dong, Zhao-Ru, additional, Hong, Jian-Guo, additional, and Li, Tao, additional

Published
2022
Full Text
View/download PDF

19. Prognostic value of soluble programmed cell death-1 (sPD-1) and soluble programmed cell death ligand-1 (sPD-L1) for hepatocellular carcinoma: a systematic review and meta-analysis

Author

Xue, Jun-shuai, primary, Liu, Hui, additional, Meng, Guang-Xiao, additional, Ding, Zi-Niu, additional, Yan, Lun-Jie, additional, Yao, Sheng-Yu, additional, Li, Hai-Chao, additional, Dong, Zhao-Ru, additional, Chen, Zhi-Qiang, additional, Hong, Jian-Guo, additional, and Li, Tao, additional

Published
2021
Full Text
View/download PDF

20. Clinical Benefit of Antiviral Agents for Hepatocellular Carcinoma Patients With Low Preoperative HBV-DNA Loads Undergoing Curative Resection: A Meta-Analysis

Author

Liu, Kai-Xuan, primary, Hong, Jian-Guo, additional, Wu, Rui, additional, Dong, Zhao-Ru, additional, Yang, Ya-Fei, additional, Yan, Yu-Chuan, additional, Yang, Chun-Cheng, additional, Yan, Lun-Jie, additional, Yao, Sheng-Yu, additional, Li, Hai-Chao, additional, Zhi, Xu-Ting, additional, and Li, Tao, additional

Published
2021
Full Text
View/download PDF

21. RECK expression is associated with angiogenesis and immunogenic Tumor Microenvironment in Hepatocellular Carcinoma, and is a prognostic factor for better survival

Author

Dong, Zhao-Ru, primary, Chen, Zhi-Qiang, additional, Yang, Xiao-Yun, additional, Ding, Zi-Niu, additional, Liu, Kai-Xuan, additional, Yan, Lun-Jie, additional, Meng, Guang-Xiao, additional, yang, Ya-Fei, additional, Yan, Yu-Chuan, additional, Yao, Sheng-Yu, additional, Yang, Chun-Cheng, additional, Zhi, Xu-Ting, additional, and Li, Tao, additional

Published
2021
Full Text
View/download PDF

22. Safety, efficacy, and survival outcomes of immune checkpoint inhibitors rechallenge in patients with cancer: a systematic review and meta-analysis.

Author

Liu SJ, Yan LJ, Wang HC, Ding ZN, Liu H, Zhang X, Pan GQ, Han CL, Tian BW, Yang XR, Tan SY, Dong ZR, Wang DX, Yan YC, and Li T

Abstract

Backgrounds: There is little evidence on the safety, efficacy, and survival benefit of restarting immune checkpoint inhibitors (ICI) in patients with cancer after discontinuation due to immune-related adverse events (irAEs) or progressive disease (PD). Here, we performed a meta-analysis to elucidate the possible benefits of ICI rechallenge in patients with cancer., Methods: Systematic searches were conducted using PubMed, Embase, and Cochrane Library databases. The objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and incidence of irAEs were the outcomes of interest., Results: Thirty-six studies involving 2026 patients were analyzed. ICI rechallenge was associated with a lower incidence of all-grade (OR, 0.05; 95%CI, 0.02-0.13, P < .05) and high-grade irAEs (OR, 0.37; 95%CI, 0.21-0.64, P < .05) when compared with initial ICI treatment. Though no significant difference was observed between rechallenge and initial treatment regarding ORR (OR, 0.69; 95%CI, 0.39-1.20, P = .29) and DCR (OR, 0.85; 95%CI, 0.51-1.40, P = 0.52), patients receiving rechallenge had improved PFS (HR, 0.56; 95%CI, 0.43-0.73, P < .05) and OS (HR, 0.55; 95%CI, 0.43-0.72, P < .05) than those who discontinued ICI therapy permanently. Subgroup analysis revealed that for patients who stopped initial ICI treatment because of irAEs, rechallenge showed similar safety and efficacy with initial treatment, while for patients who discontinued ICI treatment due to PD, rechallenge caused a significant increase in the incidence of high-grade irAEs (OR, 4.97; 95%CI, 1.98-12.5, P < .05) and a decrease in ORR (OR, 0.48; 95%CI, 0.24-0.95, P < .05)., Conclusion: ICI rechallenge is generally an active and feasible strategy that is associated with relative safety, similar efficacy, and improved survival outcomes. Rechallenge should be considered individually with circumspection, and randomized controlled trials are required to confirm these findings., (© The Author(s) 2024. Published by Oxford University Press.)

Published
2024
Full Text
View/download PDF

23. Neoadjuvant immunotherapy based on PD-1/L1 inhibitors for gastrointestinal tumors: a review of the rationale and clinical advances.

Author

Wang DX, Liu H, Tian JC, Zhang DL, Yan LJ, Ding ZN, Li H, Yan YC, Dong ZR, and Li T

Subjects
Humans, Programmed Cell Death 1 Receptor antagonists & inhibitors, Programmed Cell Death 1 Receptor immunology, B7-H1 Antigen antagonists & inhibitors, B7-H1 Antigen immunology, Neoadjuvant Therapy methods, Gastrointestinal Neoplasms immunology, Gastrointestinal Neoplasms therapy, Gastrointestinal Neoplasms drug therapy, Immunotherapy methods, Immune Checkpoint Inhibitors therapeutic use, Immune Checkpoint Inhibitors pharmacology
Abstract

The landscape of current tumor treatment has been revolutionized by the advent of immunotherapy based on PD-1/PD-L1 inhibitors. Leveraging its capacity to mobilize systemic antitumor immunity, which is primarily mediated by T cells, there is growing exploration and expansion of its potential value in various stages of clinical tumor treatment. Neoadjuvant immunotherapy induces a robust immune response against tumors prior to surgery, effectively facilitating tumor volume reduction, early eradication or suppression of tumor cell activity, and control of potential metastatic spread, to improve curative surgical resection rates, and prevent tumor recurrence. This review delineates the theoretical basis of neoadjuvant immunotherapy from preclinical research evidence, discusses specific challenges in clinical application, and provides a comprehensive overview of clinical research progress in neoadjuvant immunotherapy for gastrointestinal tumors. These findings suggest that neoadjuvant immunotherapy has the potential to ameliorate immunosuppressive states and enhance cytotoxic T cell function while preserving lymphatic drainage in the preoperative period. However, further investigations are needed on specific treatment regimens, suitable patient populations, and measurable endpoints. Despite numerous studies demonstrating the promising efficacy and manageable adverse events of neoadjuvant immunotherapy in gastrointestinal tumors, the availability of high-quality randomized controlled trials is limited, which highlights the necessity for further research., (Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results